MK-6186

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-6186, covering 2025-07-23 to 2025-07-23. Get the full timeline:

Most recent: Clinical Trial Update: MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2) [Phase 1]